Digital Healthcare Medical Oncology Congress Immunotherapy Report Released

A digital healthcare news and connection platform has launched a new report focusing on the European Society for Medical Oncology congress in Copenhagen. It covers the big breakthroughs of the event, including advances in immunotherapy.

Surrey, United Kingdom – October 30, 2016 /PressCable/ —

Pharmaphorum Media, the digital publication that brings healthcare news, information and discussions together in order for healthcare stakeholders to communicate and connect, has launched a new report on the European Society for Medical Oncology congress in Copenhagen, and the advances in immunotherapy for cancer treatment. The report explains that cancer is the most important therapeutic area for pharma, producing some of the most exciting breakthroughs and advances in treatment.

More information can be found at: http://pharmaphorum.com/views-and-analysis/esmo-review-advances-immunotherapy-ema-dialogue-patient-power.

The ESMO report says that at the event, over 1,640 studies were presented, which includes 47 late breaking trials and over 1,500 posters. In recent years, it has been the American Society of Clinical Oncology that has seen the most unveilings in regards to breakthroughs in the field. This year, however, the European counterpart has provided some of the most exciting news in the industry.

Among the most notable highlights was the new trial data from immunotherapy treatments, but other areas of notable interest were dialogue with regulators, novel trial methodologies to accelerate trials, and the continuing rise of patient power.

Dr Cristina Oliva, a senior medical director who attended the meeting, said that immunotherapy studies were presented across a range of different tumour types, covering a selection of different lines of therapy, as mono therapy and in combinations.

One of the most impressive displays was seen in the first line treatments for non-small cell lung cancer, which is known as NSCLC. Here, anti PD-1 immunotherapy pembrolizumab compared to chemotherapy showed prolonged progression free survival and overall survival. There were also fewer adverse events in patients with PD-L1 tumour expression, which is traditionally difficult to treat.

Dr Oliva went on to say that many of the data presentations and educational sessions at the event reflected radically new approaches to early stage trials. Evidence showed that regulators are trying to innovate as well, with new methodologies like adaptive pathways being implemented.

Pharmaphorum offers views and analysis on a wide range of other topics on its site, with articles and reports available at: http://pharmaphorum.com/views-and-analysis.

For more information, please visit http://pharmaphorum.com/

Contact Info:
Name: Mark Plummer
Organization: pharmaphorum media limited
Address: Rosemount House Rosemount Avenue West Byfleet,Surrey KT14 6LB United Kingdom
Phone: +44 (0)1932 339264

Release ID: 141737